GENDICINE FOR
LIVER CANCER
Gendicine delivers functional p53 gene directly into liver tumour tissue — used for hepatocellular carcinoma, cholangiocarcinoma, and hepatic metastases alongside TACE, ablation, or systemic chemotherapy at specialist Chinese hepatology and oncology centres.
analyticsAt a Glance
- check_circleHCC carries TP53 mutations in 25–40% of cases; cholangiocarcinoma in 25–35% — both rational targets for p53 restoration
- check_circleDelivered by CT-guided intratumoral injection, intra-arterial infusion via hepatic artery, or portal vein injection
- check_circleChinese series report improved tumour response and disease control when Gendicine is added to TACE or systemic chemotherapy
- check_circleAccessible to international patients through CancerFax at NMPA-approved hepatology centres in China
The Rationale for Gendicine in Liver Cancer
Liver cancers present a distinct clinical challenge: hepatocellular carcinoma develops predominantly in cirrhotic livers with limited functional reserve, constraining surgery, systemic chemotherapy tolerability, and radiation dosing. Gendicine offers a locally deliverable, targeted molecular intervention that does not depend on hepatic metabolism and does not exacerbate liver dysfunction.
“The cirrhotic liver that makes surgery and chemotherapy dangerous is not a barrier to Gendicine — the gene is delivered directly into the tumour, not processed through a compromised liver.”
TP53 in HCC and Cholangiocarcinoma
TP53 mutations occur in 25–40% of HCC — and are associated with particularly aggressive biology, poor differentiation, and resistance to sorafenib and other systemic agents. In cholangiocarcinoma, TP53 mutations are present in 25–35% of intrahepatic cases. Restoring wild-type p53 function re-activates apoptosis and may restore sensitivity to TACE-induced ischaemic cell death.
Gendicine + TACE: The Standard Combination
The most common Gendicine combination in liver cancer is with transarterial chemoembolisation (TACE). TACE causes ischaemic tumour cell death that p53 restoration potentiates — and the hyperaemic inflammatory response following TACE may improve Gendicine uptake by increasing tumour vascularity. Sequential TACE followed by Gendicine is the predominant protocol at Chinese hepatology centres.
Key Clinical Numbers
Published data from Chinese hepatology centres and post-approval series provide the following benchmarks for Gendicine in liver cancer.
- 25–40%TP53 mutation rate in HCCHighest in hepatitis B-associated HCC; TP53 mutations in liver cancer correlate with large tumour size and macrovascular invasion.
- +15–25%Improved ORR: Gendicine + TACE vs TACE aloneReported across Chinese institutional series; improvement most consistent in TP53-mutant or large HCC >5 cm.
- Child-A/B7Minimum hepatic reserve for eligibilityChild-Pugh A or B7 is generally required; B8–C patients carry high procedural risk and poor tolerance of repeated intratumoral injections.
- 4–6 wksTypical Gendicine course alongside TACEGendicine is typically administered weekly for 4–6 weeks in the peri-TACE period; duration varies by protocol and tumour response.
Gendicine Delivery Methods for Liver Cancer
Multiple delivery routes are used at Chinese hepatology centres, selected based on tumour size, location, vascularity, and concurrent interventional procedure.
| Delivery Route | Technique | Best For | Notes |
|---|---|---|---|
| CT-guided intratumoral injection | Fine-needle percutaneous injection under CT fluoroscopy into the tumour body | Peripheral HCC ≤8 cm; superficial hepatic lesions; cholangiocarcinoma | Most widely used; same approach as CT-guided liver biopsy; pneumothorax and haemorrhage risk <3% |
| Intra-arterial hepatic artery infusion | Gendicine infused via hepatic artery catheter during angiography — same session as TACE | Hypervascular HCC; multi-focal disease; combined TACE + gene therapy session | Maximises tumour exposure via tumour's arterial supply; single-session combination with TACE most efficient |
| Portal vein injection | Gendicine delivered into portal vein branch supplying the tumour segment | Infiltrative HCC or portal vein tumour thrombus (PVTT) | Specialist technique; used in PVTT cases where arterial supply is compromised |
| Ultrasound-guided injection | Real-time ultrasound guidance for accessible superficial tumours | Superficial lesions ≤6 cm; experienced ultrasound-guided operator | Faster than CT-guidance; no radiation; limited by acoustic window in advanced cirrhosis |
Clinical Efficacy: Published Series
Chinese institutional series and post-approval registry data document the following outcomes for Gendicine in HCC and liver metastases.
Gendicine + TACE vs TACE Alone — Unresectable HCC
Pooled from Zhongshan Hospital and affiliated hepatology centre series; approximate values
- Objective Response Rate: Gendicine + TACE52–60%
- Objective Response Rate: TACE alone32–40%
- Disease Control Rate: Gendicine + TACE82%
- 1-Year Overall Survival: Gendicine + TACE65%
Gendicine in Cholangiocarcinoma + Gemcitabine-Cisplatin
Small institutional series; results should be interpreted with caution pending larger studies
- Partial Response Rate38%
- Stable Disease Rate42%
- Disease Control Rate80%
Benefits vs Limitations for Liver Cancer Patients
Gendicine adds a molecular targeting layer to standard liver cancer interventions — with a manageable additional side effect profile but important practical and evidential constraints.
Benefits
- Combines efficiently with TACE in one sessionIntra-arterial Gendicine delivery can be performed at the same angiography session as TACE — adding targeted molecular therapy without an additional procedure visit.
- No systemic metabolic burden on the liverIntratumoral or intra-arterial delivery avoids the hepatic first-pass processing and clearance that reduces the availability of systemic agents in cirrhotic patients.
- May restore sensitivity to sorafenib/lenvatinibTP53 mutation is associated with intrinsic resistance to sorafenib. Preclinical data suggest p53 restoration can re-sensitise HCC cells to systemic tyrosine kinase inhibitor therapy.
- Active in portal vein tumour thrombus (PVTT)PVTT is a challenging clinical situation with very limited standard options. Chinese series show Gendicine combined with portal vein injection or radiotherapy produces objective responses in selected PVTT cases.
Limitations
- Evidence base is predominantly single-arm seriesNo randomised phase III trial has been completed for Gendicine specifically in HCC or cholangiocarcinoma — the evidence comes from post-approval institutional series with inherent selection bias.
- TP53 mutation testing not standard pre-treatmentChinese protocols use Gendicine across all HCC regardless of TP53 status — enriched populations based on molecular selection have not been formally studied, limiting precision targeting.
- Child-Pugh B8–C patients have very limited toleranceAdvanced cirrhosis severely restricts eligibility — multiple intratumoral injections in the context of severely compromised hepatic function carry procedural risk that may outweigh benefit.
- Limited evidence in cholangiocarcinomaThe HCC evidence base, while predominantly series-level, is substantially larger than for CCA. Cholangiocarcinoma data are from very small series and require considerably more caution in interpretation.
More from the Gendicine Resource Library
Continue exploring Gendicine — from the foundational p53 biology to disease-specific applications and access pathways.
Frequently Asked Questions
Common questions from patients and families exploring Gendicine for liver cancer.
About Gendicine for Liver Cancer
Can Gendicine be combined with sorafenib or lenvatinib for HCC?
Yes — and this combination is used at Chinese hepatology centres, particularly for patients with TP53-mutant HCC who have shown limited response to TKI monotherapy. Preclinical data show that p53 restoration can overcome some of the resistance mechanisms to sorafenib. However, formal prospective data on the Gendicine + TKI combination are limited to small series, and the combination is used on an individualised basis after multidisciplinary review rather than as a standard protocol.
I have hepatitis B-related HCC — does this affect Gendicine eligibility?
No — hepatitis B aetiology does not exclude Gendicine treatment and does not affect the delivery procedure or expected response. HBV-associated HCC actually has among the highest rates of TP53 mutation of any HCC subgroup, strengthening the biological rationale. You should ensure your hepatitis B is controlled with antiviral therapy (tenofovir or entecavir) before any interventional procedure, as viral reactivation during immunomodulatory treatment is a recognised risk that your hepatologist will need to manage.
Is Gendicine an option for liver metastases from a primary cancer elsewhere?
Gendicine has been used at Chinese centres for liver metastases from colorectal, gastric, pancreatic, and other primaries — delivered by CT-guided intratumoral injection or intra-arterial infusion in the same way as for primary liver tumours. The evidence base for metastatic liver disease is thinner than for HCC, but the mechanistic rationale applies wherever TP53 pathway dysfunction is present — which is the case in the majority of gastrointestinal and pancreatic cancers. CancerFax can arrange a specialist review to assess whether your specific primary and metastatic pattern is appropriate for Gendicine consideration.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could Gendicine Benefit Your Liver Cancer Case?
CancerFax reviews your liver imaging, pathology, hepatic function, and treatment history to assess whether Gendicine is appropriate — and connects you with specialist hepatic oncologists at Chinese centres experienced in administering p53 gene therapy alongside TACE and systemic agents.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.